targeting hif-2a in the management of vhl-associated rcc
Published 4 years ago • 115 plays • Length 3:29Download video MP4
Download video MP3
Similar videos
-
4:58
current concepts in the management of vhl
-
4:13
novel hif-2a inhibitor for patients with advanced renal cell carcinoma
-
2:21
phase ii study of the oral hif-2α inhibitor mk-6482 for vhl ccrcc: update
-
4:39
clear cell rcc: vhl/hif pathway
-
3:00
pt2977 for vhl-associated rcc
-
4:53
data from von-hippel-lindau clinical trial shows promise for hif-2a inhibitor
-
22:30
vhl breakthrough: an expert discussion
-
3:45
explanation video: the role of the hypoxia inducible factor (hif) in the regulation of oxygen
-
1:19
hif-2 inhibitors in rcc
-
1:16
dr. jonasch on the safety profile of mk-6482 in von hippel-lindau disease–associated rcc
-
1:48
dr. jonasch on next steps with mk-6482 in von hippel-lindau disease–associated rcc
-
2:48
oral hif-2 α inhibitor mk-6482 in patients with advanced clear cell renal cell carcinoma
-
2:52
litespark-004: esa use in vhl disease-associated rcc
-
2:44
novel von hippel-lindau syndrome therapies inhibiting hif-2α
-
2:21
phase ii study of the oral hif-2α inhibitor mk-6482
-
4:32
pazopanib for patients with von hippel-lindau (vhl) disease
-
1:51
kidney cancer research: hif-2α inhibition
-
58:42
"von hippel-lindau disease", a scientific lecture by nobel laureate william g. kaelin
-
6:09
belzutifan for vhl disease-associated renal cell carcinoma